Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer

Gynecologic Oncology

Volumn 106, Issue 1, 2007, Pages 112-118

  Simon, Iris ^a   Liu, Yan ^b   Krall, Kirstin L ^a   Urban, Nicole ^b   Wolfert, Robert L ^a   Kim, Nam W ^a   McIntosh, Martin W ^b  

^a diaDexus Inc   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

CA125 multivariate analysis; Ovarian cancer; Serum marker; Tumor marker

Indexed keywords

B7 H4 ANTIGEN; BIOLOGICAL MARKER; CA 125 ANTIGEN; DCR3 ANTIBODY; SPONDIN 2; TUMOR MARKER; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CANCER TISSUE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE MARKER; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; GENE OVEREXPRESSION; GENOMICS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MARKER GENE; OVARY CANCER; PRIORITY JOURNAL; ROC CURVE; SENSITIVITY AND SPECIFICITY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD80; CA-125 ANTIGEN; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MICE; MICE, INBRED BALB C; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; TUMOR MARKERS, BIOLOGICAL;

EID: 34250208454     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.03.007     Document Type: Article

References (36)

1. Edwards B.K., Brown M.L., Wingo P.A., Howe H.L., Ward E., Ries L.A.G., et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J. Natl. Cancer Inst. 97 (2005) 1407-1427
2. American Cancer Society. Cancer facts and figures 2005 [online]. Atlanta, GA, available from: URL: http://www.cancer.org/docroot/stt/stt_0.asp.
3. Buys S.S., Partridge E., Greene M.H., Porok P.C., Reding D., Riley T.L., et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of randomized trial. AJOG 193 (2005) 1630-1639
4. Jacobs I.J., and Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol. Cell. Proteomics 3.4 (2004) 355-366
5. Bell R., Petticrew M., and Sheldon T. The performance of screening tests for ovarian cancer: results of a systematic review. Br. J. Obstet. Gynaecol. 105 (1998) 1136-1147
6. van Nagell Jr. J.R., DePriest P.D., Reedy M.B., Gallion H.H., Ueland F.R., Pavlic E.J., et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol. Oncol. 77 (2000) 350-356
7. Sato S., Yokoyama Y., Sakamoto T., Futagami M., and Saito Y. Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography. Cancer 89 (2000) 582-588
8. Markman M. The role of CA 125 in the management of ovarian cancer. Oncologist 2 (1997) 6-9
9. Stirling D.D., Evans G.R., Pichert G., Shenton A., Kirk E.N., Rimmer S., et al. Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the International Federation of Gynecology and Obstetrics system. J. Clin. Oncol. 23 (2005) 5588-5596
10. Jacobs I.J. Screening for familial ovarian cancer: the need for well-designed prospective studies. J. Clin. Oncol. 24 (2005) 5443-5445
11. Bast R.C., Urban N., Shridhar V., et al. Early detection of ovarian cancer: promise and reality. In: Stack M.S., and Fishman D.A. (Eds). Ovarian cancer. Cancer research and treatment vol. 107 (2001), Kluwer Academic Publishers, Boston 61-97
12. Salceda S., Tang T., Kmet M., et al. The immuno-modulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp. Cell Res. 306 (2005) 128-141
13. Zang X., Loke P., Kim J., Murphy K., Waitz R., and Allison J.P. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc. Natl. Acad. Sci. 100 (2003) 10388-10392
14. Sica G.L., Choi I.H., Zhu G., Tamada K., Wang S.D., Chapoval A.I., et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18 (2003) 849-861
15. Collins M., Ling V., and Carreno B.M. The B7 family of immune-regulatory ligands. Genome Biol. 6 (2005) 223.1-223.7
16. Tringler B., Zhuo S., Pilkington G., et al. B7-H4 is highly expressed in ductal and lobular breast cancer. Clin. Cancer Res. 11 (2005) 1842-1848
17. Tringler B., Liu W., Corral L., et al. B7-H4 over-expression in ovarian cancer. Gynecol. Oncol. 100 (2006) 44-52
18. Simon I., Zhou S., Corral L., Diamandis E.P., Sarno M.J., Wolfert R.L., et al. B7-H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res. 66 (2006) 1570-1575
19. Feinstein Y., Borrell V., Garcia C., Burstyn-Cohen T., Tzarfaty V., Frumkin A., et al. F-spondin and mindin: two structurally and functionally related genes expressed in the hippocampus that promote outgrowth of embryonic hippocampal neurons. Development 126 (1999) 3637-3648
20. Klar A., Baldassare M., and Jessell T.M. F-spondin: a gene expressed at high levels in the floor plate encodes a secreted protein that promotes neural cell adhesion and neurite extension. Cell 69 (1992) 95-110
21. Parry R., Schneider D., Hudson D., et al. Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer. Cancer Res. 65 (2005) 8397-8405
22. He Y.W., Li H., Zhang J., et al. The extracellular matrix protein mindin is a pattern-recognition molecule for microbial pathogens. Nat. Immunol. 5 (2004) 88-89
23. Jia W., Li H., and He Y.W. The extracellular matrix protein mindin serves as an integrin ligand and is critical for inflammatory cell recruitment. Blood 106 (2005) 3854-3859
24. Pitti R.M., Marsters S.A., Lawerence D.A., Roy M., Kischkel F.C., and Dowd P. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396 (1998) 699-703
25. Wu Y., Han B., Sheng H., Moore P.A., Zhang J., and Wu J. Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. Int. J. Cancer 105 (2003) 724-732
26. Chen J., Zhang L., and Kim S. Quantification and detection of DcR3, a decoy receptor in TNFR family. J. Immunol. Methods 285 (2004) 63-70
27. McIntosh M.W., Drescher C., Karlan B., Scholler N., Urban N., Hellstrom K.E., et al. Combining CA125 and SMR serum markers for diagnosis and early detection of ovarian cancer. Gynecol. Oncol. 95 (2004) 9-15
28. McIntosh M.W., and Pepe M. Combining several screen tests: optimality of the risk score. Biometrics 58 (2002) 657-664
29. Sato A., and McIntosh M. Evaluating the performance of adaptive compared to non-adaptive screening rules for cancer when using serum biomarkers (2004), Department of Biostatistics Seattle, University of Washington
30. Skates C.J., Pauler D.K., and Jacobs I. Screening based on the risk of cancer calculation from Bayesian Hierarchical Change-point models of longitudinal markers. J. Am. Stat. Assoc. 96 (2001) 429-439
31. McIntosh M., Urban N., and Karlan B. Generating longitudinal screening algorithms using novel biomarkers for disease. Cancer Epidemiol., Biomarkers Prev. 11 (2002) 159-166
32. Jacobs I., and Bast Jr. R.C. The CA125 tumour-associated antigen: a review of the literature. Hum. Reprod. 4 (1989) 1-12
33. Simon I., Kim N.W., Kuo T., et al. Ovr110: a potential serum marker for early detection of ovarian cancer. AACR 95th Annual Meeting 2004 Proceedings vol. 45 (2004) 913-914 [abstr.]
34. Smith L.H., Morris C.R., Yasmeen S., Parikh-Patel A., Cress R.D., and Romano P.S. Ovarian cancer: can we make the clinical diagnosis earlier?. Cancer 104 (2005) 1398-1407
35. Jacobs I.J., Skates S.J., MacDonald N., Menon U., Rosenthal U., Davies A., et al. Screening for ovarian cancer: a pilot randomized controlled trial. Lancet 353 (1999) 1207-1210
36. Urban N., and Drescher C. Current and future developments in screening for ovarian cancer. Women's Health 2 5 (2006) 733-742